160 related articles for article (PubMed ID: 36128634)
1. Treatment of otomycosis with clotrimazole: results accordingly with the fungus isolated.
Antunes J; Mendes N; Adónis C; Freire F
Acta Otolaryngol; 2022; 142(9-12):664-667. PubMed ID: 36128634
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of topical clotrimazole vs. topical tolnaftate in the treatment of otomycosis. A randomized controlled clinical trial.
Jimenez-Garcia L; Celis-Aguilar E; Díaz-Pavón G; Muñoz Estrada V; Castro-Urquizo Á; Hernández-Castillo N; Amaro-Flores E
Braz J Otorhinolaryngol; 2020; 86(3):300-307. PubMed ID: 30826311
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the recovery rate of otomycosis using betadine and clotrimazole topical treatment.
Mofatteh MR; Naseripour Yazdi Z; Yousefi M; Namaei MH
Braz J Otorhinolaryngol; 2018; 84(4):404-409. PubMed ID: 28549873
[TBL] [Abstract][Full Text] [Related]
4. Otomycosis in immunocompetent and immunocompromised patients: comparative study and literature review.
Viswanatha B; Sumatha D; Vijayashree MS
Ear Nose Throat J; 2012 Mar; 91(3):114-21. PubMed ID: 22430336
[TBL] [Abstract][Full Text] [Related]
5. Various topical antifungal agents in otomycosis, which is the best?
Jwery AK
J Pak Med Assoc; 2021 Dec; 71(Suppl 8)(12):S32-S34. PubMed ID: 35130214
[TBL] [Abstract][Full Text] [Related]
6. Topical azole treatments for otomycosis.
Lee A; Tysome JR; Saeed SR
Cochrane Database Syst Rev; 2021 May; 5(5):CD009289. PubMed ID: 34033120
[TBL] [Abstract][Full Text] [Related]
7. Clinical and microbial epidemiology of otomycosis in the city of Yasuj, southwest Iran, revealing Aspergillus tubingensis as the dominant causative agent.
Sabz G; Gharaghani M; Mirhendi H; Ahmadi B; Gatee MA; Sisakht MT; Hemati A; Mohammadi R; Taghavi J; Nouripour-Sisakht S
J Med Microbiol; 2019 Apr; 68(4):585-590. PubMed ID: 30801244
[TBL] [Abstract][Full Text] [Related]
8. Role of Clotrimazole in Prevention of Recurrent Otomycosis.
Kiakojuri K; Rajabnia R; Mahdavi Omran S; Pournajaf A; Karami M; Taghizadeh Armaki M
Biomed Res Int; 2019; 2019():5269535. PubMed ID: 31950041
[TBL] [Abstract][Full Text] [Related]
9. Species distribution patterns and epidemiological characteristics of otomycosis in Southeastern Serbia.
Tasić-Otašević S; Golubović M; Đenić S; Ignjatović A; Stalević M; Momčilović S; Bojanović M; Arsić-Arsenijević V
J Mycol Med; 2020 Sep; 30(3):101011. PubMed ID: 32693980
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic Aspergillus Strains Identification and Antifungal Susceptibility Analysis of 452 Cases with Otomycosis in Jingzhou, China.
Peng D; Li A; Kong M; Mao C; Sun Y; Shen M
Mycopathologia; 2024 Apr; 189(2):30. PubMed ID: 38578519
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Clotrimazole 1% Solution Compared to Econazole Nitrate 1% + Triamcinolone Acetonide 0.1% Cream in Patient with Otomycosis.
Mostafa MG; Ahmed S; Islam MR; Rahman MA; Khan L; Alam MM; Ahmed MB
Mymensingh Med J; 2021 Jul; 30(3):638-643. PubMed ID: 34226449
[TBL] [Abstract][Full Text] [Related]
12. Ear Infections by Non albicans Candida Species with Isolation of Rare Drug Resistant Species in a Tertiary Care Hospital of Bangladesh.
Alam MM; Biplob JA; Sathi FA; Nila SS; Paul A; Khanam J; Chowdhury CS; Khan MS
Mymensingh Med J; 2023 Jul; 32(3):644-648. PubMed ID: 37391953
[TBL] [Abstract][Full Text] [Related]
13. Molecular Identification and In Vitro Antifungal Susceptibility of Aspergillus Isolates Recovered from Otomycosis Patients in Western China.
Zhang L; Wang X; Houbraken J; Mei H; Liao W; Hasimu H; Liu W; Deng S
Mycopathologia; 2020 Jun; 185(3):527-535. PubMed ID: 32346838
[TBL] [Abstract][Full Text] [Related]
14. Screening Candida auris through a multiplex stepwise PCR algorithm directly from clinical samples of patients suspected of otomycosis in south of Iran; Detection of five cases.
Naeimi B; Safari F; Ahmadikia K; Ahmadipour MJ; Sadeghzadeh F; Kondori N; Ahmadi B
Mycoses; 2024 Jan; 67(1):e13686. PubMed ID: 38214363
[TBL] [Abstract][Full Text] [Related]
15. Species identification and in vitro antifungal susceptibility testing of Aspergillus section Nigri strains isolated from otomycosis patients.
Kamali Sarwestani Z; Hashemi SJ; Rezaie S; Gerami Shoar M; Mahmoudi S; Elahi M; Bahardoost M; Tajdini A; Abutalebian S; Daie Ghazvini R
J Mycol Med; 2018 Jun; 28(2):279-284. PubMed ID: 29540288
[TBL] [Abstract][Full Text] [Related]
16. [Otomycosis: the modern view of etiology and management].
Kryukov AI; Kunel'skaya NL; Kunel'skaya VY; Ivoilov AY; Turovskiy AB; Shadrin GB; Machulin AI
Vestn Otorinolaringol; 2018; 83(1):48-51. PubMed ID: 29488497
[TBL] [Abstract][Full Text] [Related]
17. Molecular epidemiology of otomycosis in Isfahan revealed a large diversity in causative agents.
Aboutalebian S; Mahmoudi S; Mirhendi H; Okhovat A; Abtahi H; Chabavizadeh J
J Med Microbiol; 2019 Jun; 68(6):918-923. PubMed ID: 31063125
[TBL] [Abstract][Full Text] [Related]
18. Otomycosis in Africa: Epidemiology, diagnosis and treatment.
Sangaré I; Amona FM; Ouedraogo RW; Zida A; Ouedraogo MS
J Mycol Med; 2021 Jun; 31(2):101115. PubMed ID: 33516991
[TBL] [Abstract][Full Text] [Related]
19. First molecular report of causative agent of otomycosis due to Aspergillus luchuensis.
Sarvestani HK; Ghazvini RD; Hashemi SJ; Rezaie S; Mahmoudi S; Shoar MG; Elahi M; Izadi A; Getso MI; Rafat Z; Tajdini A; Hedayati MT
J Wound Care; 2021 Sep; 30(Sup9a):XIVi-XIViii. PubMed ID: 34597173
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of 3 per cent boric acid in 70 per cent alcohol versus 1 per cent clotrimazole solution in otomycosis patients: a randomised, controlled trial.
Romsaithong S; Tomanakan K; Tangsawad W; Thanaviratananich S
J Laryngol Otol; 2016 Sep; 130(9):811-5. PubMed ID: 27477534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
